

Syngene

Ref: Syn/CS/SE/Reg 30/2024-25/Jun/02

Syngene International Limited
Biocon SEZ, Biocon Park, Plot No. 2 &
3, Bommasandra Industrial Area, IV
Phase, Jigani Link Road, Bengaluru
560 099, Karnataka, India
T +91 80 6891 8000
F +91 80 6775 8808
CIN: L85110KA1993PLC014937
www.syngeneintl.com

June 01, 2024

To, The Manager, BSE Limited Corporate Relationship Department Dalal Street, Mumbai – 400 001	To, The Manager, National Stock Exchange of India Limited Corporate Communication Department Bandra (EAST), Mumbai – 400 051
Scrip Code: 539268	Scrip Symbol: SYNGENE

Dear Sir/Ma'am,

Subject: Intimation under Regulation 30 of the Securities & Exchange Board of India (Listing Obligations & Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations") – Appointment of Independent Director

Pursuant to Regulation 30 of the SEBI Listing Regulations, we wish to inform you that the Board of Directors of the Company, based on the recommendation of the Nomination and Remuneration Committee, has approved the appointment of Ms. Manja Boerman as an Additional Director (Independent, Non-Executive) with effect from the date of allotment of Director Identification Number (DIN) until the Annual General Meeting to be held in the year 2027, subject to the approval of the shareholders. The Company shall inform the Stock exchanges once the DIN has been allotted.

The details required in terms of Regulation 30, read with Schedule III of the SEBI Listing Regulations and SEBI Circulars issued in this regard, are enclosed as "**Annexure – I**".

It may be noted that Ms. Manja Boerman satisfies the criteria of independence prescribed under the Companies Act, 2013 ("Act") and SEBI Listing Regulations and is not debarred from holding the office of Director by virtue of any order passed by SEBI or any other such authority.

Further, the composition of the Board of Directors of the Company is in compliance with the requirements prescribed under the Act and SEBI Listing Regulations.

The above-mentioned information will also be made available on the website of the Company www.syngeneintl.com.

Request to kindly take this intimation on record.

Thanking You,

Yours faithfully,

For **SYNGENE INTERNATIONAL LIMITED**

Priyadarshini Mahapatra
Head Legal & Company Secretary

Information as required under Regulation 30 - Part A of Para A of Schedule III of SEBI Listing Regulations and SEBI Circulars

S. No.	Particulars	Description
1.	Reason for Change viz. appointment, re-appointment, resignation, removal, death or otherwise	Appointment.
2.	Date of appointment/ re-appointment/cessation (as applicable) & term of appointment/re-appointment;	With effect from the date of allotment of Director Identification Number (DIN) until the Annual General Meeting to be held in the year 2027, subject to the approval of the shareholders.
3.	Brief Profile (in case of appointment of a Director)	<p>Manja Boerman is a distinguished leader in the biopharmaceutical industry with a deep specialization in protein, cell and gene therapy. With over 20 years of experience, she has played pivotal roles in numerous companies, significantly impacting the development and commercialization of advanced therapies. Manja's career highlights include her tenure as President of Catalent Protein, Cell and Gene Therapy, Aesica Pharmaceuticals, Patheon Biologics, and DSM Biologics, as well as her leadership as CEO of Kiadis Pharma and Regenesance. She is currently the CEO of Prothya Biosolutions (a blood plasma product company).</p> <p>Manja holds a PhD in Biochemistry from the State University of New York, reflecting her strong academic background in life sciences. She began her career at DSM, where she held various positions in business development, licensing, and technology within DSM Biologics.</p> <p>Throughout her career, Manja has been recognized for her expertise in clinical operations, strategic planning, and business development. She has contributed to numerous scientific publications and has been a prominent speaker at industry conferences. Her ability to drive growth and foster innovation has earned her a respected reputation in the biotechnology sector, particularly in start-up environments and global late-stage clinical development for cell therapy products.</p>
4.	Disclosure of relationships between Directors (in case of appointment of Director)	Manja Boerman is not related to any of the Directors of the Company.